Dianthus Therapeutics, Inc. (NASDAQ: DNTH) completed its underwritten public offering, raising approximately $719 million in gross proceeds before fees and expenses, according to a company statement.

The biotechnology company sold 8,470,989 shares of common stock at $81.00 per share, including 1,157,407 additional shares from the full exercise of underwriters' overallotment option. The company also issued pre-funded warrants to purchase up to 402,468 shares at $80.999 per warrant to certain investors in lieu of common stock.

The pre-funded warrants carry an exercise price of $0.001 per share and are immediately exercisable. The offering closed on March 12, 2026.

Dianthus stated it plans to use net proceeds to advance clinical and preclinical development activities, commercial readiness activities, working capital and general corporate purposes.

Jefferies, TD Cowen, Evercore ISI, Stifel, Guggenheim Securities and William Blair served as joint book-running managers for the offering. LifeSci Capital acted as financial advisor.

The offering was conducted under a shelf registration statement on Form S-3 that became effective on January 30, 2026, and a related registration statement filed March 10, 2026.

Dianthus develops therapies for autoimmune diseases and operates from New York City and Waltham, Massachusetts.